Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$28.52
-0.38 (-1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-68.8M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
95.1x
↑EV/EBITDA
38.0x
↑ROE
2.4%
↑Gross Margin
76.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.8%
FCF CAGR
—
FCF margin
-7.4%
FCF / Net income
-0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $234.8M · net income $21.9M · FCF $-17.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $234.8M | $234.8M | $256.4M | $225.5M | $255.5M |
| Net Income | $21.9M | $21.9M | $40.3M | $50.5M | $40.7M |
| EBITDA | $56.9M | $56.9M | $69.1M | $77.0M | $58.4M |
| EPS | 0.29 | 0.29 | 0.52 | 0.63 | 0.53 |
| Gross Margin | 76.3% | 76.3% | 76.5% | 80.3% | 81.6% |
| Operating Margin | 7.3% | 7.3% | 15.9% | 16.7% | 15.6% |
| Net Margin | 9.3% | 9.3% | 15.7% | 22.4% | 15.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.00 | — |
| Current Ratio | 3.88 | 3.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-17.4M | $-17.4M | $-80.7M | $-68.8M | $12.8M |
| Returns | |||||
| ROE | 2.4% | 2.4% | 4.4% | 5.1% | 4.3% |
| Valuation | |||||
| P/E | 95.07 | 95.07 | 47.86 | 44.69 | 55.89 |
| EV/EBITDA | 38.04 | 38.04 | 25.28 | 24.99 | 35.49 |
| P/B | 2.41 | 2.41 | 2.13 | 2.30 | 2.41 |
| Growth & Yield | |||||
| Revenue Growth | -8.4% | -8.4% | 13.7% | -11.7% | — |
| EPS Growth | -44.7% | -44.7% | -17.2% | 18.8% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
106.8%
EPS terminal req.
$2.53
Spread vs growth
-151.4%
5Y implied EPS CAGR
60.6%
EPS terminal req.
$3.06
Spread vs growth
-105.3%
10Y implied EPS CAGR
32.9%
EPS terminal req.
$4.93
Spread vs growth
-77.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.2%
Start / end P/E
54.2x → 99.6x
EPS bridge
0.52 → 0.29
Residual
-37.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.